Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates

详细信息    查看全文

• 作者：Jennifer I. Smart^c ; ¹ ; ^{jsmart@smartmicrobiology.com} ; G. Ralph Corey^a ; Martin E. Stryjewski^b ; Whedy Wang^c ; Steven L. Barriere^c ; ¹
• 关键词：Telavancin ; S. aureus ; Lipoglycopeptide ; Complicated skin and skin-structure infection
• 刊名：Diagnostic Microbiology and Infectious Disease
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：87
• 期：3
• 页码：268-271
• 全文大小：194 K
• 卷排序：87

文摘

The rBMD method has improved the accuracy and reproducibility of telavancin MIC testing. The objective of this study was to analyze the S. aureus isolates recovered from complicated skin and skin-structure infections patients treated using the rBMD method and evaluate the impact of the revised MICs on the clinical cure and microbiological eradication rates. Telavancin MIC values obtained by the rBMD were up to 8-fold lower than the values obtained by the original BMD method and all isolates remained susceptible to telavancin at the 0.12 μg/mL breakpoint. The clinical cure and microbiological eradication rates were comparable for patients with S. aureus, methicillin-resistant S. aureus, and S. aureus isolates with elevated vancomycin MICs (≥1 μg/mL). With the revision of the BMD method, telavancin MICs more accurately represent telavancin's in vitro potency against S. aureus.